Bloomberg Law
Bankruptcy
LinkedIn

Bausch + Lomb to Buy InflammX Therapeutics; No Terms

Jan. 10, 2025, 1:39 PM UTC
Cameron Baker
Cameron Baker

InflammX Therapeutics to be acquired by Bausch + Lomb, terms of the transaction were not disclosed.

  • InflammX is a biotech company focusing on retinal diseases
  • Pact signed Dec. 2024 gives Bausch the option to buy based on achievement of certain development milestones

To view the source of this information, click here

To contact the reporter on this story:
Cameron Baker in Boston at cbaker225@bloomberg.net

To contact the editor responsible for this story:
Zachary Fleming at zfleming2@bloomberg.net

© 2025 Bloomberg L.P. All rights reserved. Used with permission.

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.